Norwood, Mass.-based Corbus Pharmaceuticals Holdings Inc. appointed John Jenkins to its board.
Jenkins is a former director of the Office of New Drugs at the U.S. Food and Drug Administration's Center for Drug Evaluation and Research, having served in the role from 2002 to 2017. During his time at the FDA, he was responsible for reviewing new drug applications and biological licensing applications and approval of new molecular entities.
He is expected to help Corbus advance its cystic fibrosis drug lenabasum to potential regulatory approval.
